LYPD6B: A Protein with Potential as A Drug Target Or Biomarker

Target Name: LYPD6B

NCBI ID: G130576

LYPD6B

LYPD6B: A Protein with Potential as A Drug Target Or Biomarker

LYPD6B (lysine-rich protein 6B) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is characterized by the presence of a specific lysine residue in its sequence, which is known as LYPD6B_HUMAN. LYPD6B has been shown to play a role in various physiological processes in the body, including cell signaling, DNA replication, and inflammation. As a result, LYPD6B has potential as a drug target or biomarker.

The LYPD6B protein is composed of 21 kilodalton (kDa) of amino acids, and its molecular weight is approximately 30 kDa. The protein is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is primarily localized to the cytoplasm of cells, and is also found in the endoplasmic reticulum (ER) and the nuclear envelope (NE).

One of the unique features of LYPD6B is the presence of a specific lysine residue in its sequence, known as LYPD6B_HUMAN. This lysine residue is a key structural feature that gives the protein its name and is responsible for its unique structure. The LYPD6B_HUMAN lysine residue is located at position 193 amino acids (aa) residue 111-112, and is a key structural feature that is involved in the stability and structure of the protein.

The role of LYPD6B in cell signaling is well established. LYPD6B has been shown to play a role in various signaling pathways, including the regulation of cell adhesion, the regulation of cell proliferation, and the regulation of cell differentiation. LYPD6B has also been shown to interact with various proteins, including the protein tyrosine kinase (PTK), which is involved in cell signaling.

In addition to its role in cell signaling, LYPD6B has also been shown to play a role in DNA replication and transcription. LYPD6B has been shown to interact with the protein histone H3, which is involved in the regulation of DNA replication and transcription. This interaction between LYPD6B and H3 suggests that LYPD6B may be involved in the regulation of DNA replication and transcription.

The role of LYPD6B in inflammation is also well established. LYPD6B has been shown to play a role in the regulation of various inflammatory responses, including the regulation of inflammation and the regulation of inflammation-related pain. LYPD6B has also been shown to interact with various proteins involved in inflammation, including the protein NF-kappa-B.

As a result of its unique structure and its involvement in various physiological processes, LYPD6B has potential as a drug target or biomarker. Studies have shown that LYPD6B can be targeted by small molecules, including inhibitors of tyrosine kinase (TK) signaling, which is involved in cell signaling. In addition, LYPD6B has also been shown to interact with various proteins involved in inflammation, including the protein NF-kappa-B. These interactions suggest that LYPD6B may be a useful target for the development of new therapies for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

In conclusion, LYPD6B is a unique protein that is expressed in various tissues of the human body and is characterized by the presence of a specific lysine residue in its sequence, known as LYPD6B_HUMAN. LYPD6B has been shown to play a role in various physiological processes in the body, including cell signaling, DNA replication, and inflammation. As a result, LYPD6B has potential as a drug target or biomarker, and studies are being conducted to determine its full role in the regulation of various physiological processes in the body.

Protein Name: LY6/PLAUR Domain Containing 6B

Functions: Likely acts as a modulator of nicotinic acetylcholine receptors (nAChRs) activity (PubMed:34631692, PubMed:26586467). In vitro acts on nAChRs in a subtype- and stoichiometry-dependent manner (PubMed:26586467). Modulates specifically alpha-3(3):beta-4(2) nAChRs by enhancing the sensitivity to ACh, decreasing ACh-induced maximal current response and increasing the rate of desensitization to ACh; has no effect on alpha-7 homomeric nAChRs; modulates alpha-3(2):alpha-5:beta-4(2) nAChRs in the context of CHRNA5/alpha-5 variant Asn-398 but not its wild-type sequence (PubMed:26586467). However, according to another report in vitro it can weakly inhibits alpha-7 nAChRs (PubMed:34631692)

The "LYPD6B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYPD6B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets